Aggarwal Arpit, Schrimpf Lindsey, Lauriello John
Clin Schizophr Relat Psychoses. 2018 Jan;11(4):221-223. doi: 10.3371/CSRP.AGSC.010318.
Bipolar I disorder is a serious and disabling psychiatric illness. It is associated with a significant reduction in quality of life and an increased risk for suicide. Pharmacotherapy is essential for both the acute and maintenance treatment of bi-polar I disorder. While multiple oral medications are recommended for the maintenance treatment, there are not many long-acting injectable medications approved for this indication. New treatments that would improve patient adherence have the potential for decreasing relapses and improving patients' ability to remain functional members of society. In this paper we discuss the available data for safety and efficacy of aripiprazole long-acting injectable in bipolar disorder.
双相 I 型障碍是一种严重且致残的精神疾病。它与生活质量显著下降以及自杀风险增加有关。药物治疗对于双相 I 型障碍的急性期和维持期治疗都至关重要。虽然推荐多种口服药物用于维持治疗,但获批用于该适应症的长效注射药物并不多。能够提高患者依从性的新治疗方法有可能减少复发,并提高患者作为社会功能性成员的能力。在本文中,我们讨论了阿立哌唑长效注射剂治疗双相情感障碍的安全性和有效性的现有数据。